Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Invested Capital (2016 - 2025)

Ocular Therapeutix has reported Invested Capital over the past 13 years, most recently at $654.3 million for Q4 2025.

  • Quarterly results put Invested Capital at $654.3 million for Q4 2025, up 107.49% from a year ago — trailing twelve months through Dec 2025 was $654.3 million (up 107.49% YoY), and the annual figure for FY2025 was $654.3 million, up 107.49%.
  • Invested Capital for Q4 2025 was $654.3 million at Ocular Therapeutix, up from $258.2 million in the prior quarter.
  • Over the last five years, Invested Capital for OCUL hit a ceiling of $654.3 million in Q4 2025 and a floor of $3.1 million in Q2 2023.
  • Median Invested Capital over the past 5 years was $109.1 million (2021), compared with a mean of $188.9 million.
  • Biggest five-year swings in Invested Capital: crashed 95.31% in 2023 and later skyrocketed 12135.02% in 2024.
  • Ocular Therapeutix's Invested Capital stood at $113.0 million in 2021, then crashed by 46.57% to $60.4 million in 2022, then surged by 113.04% to $128.6 million in 2023, then surged by 145.15% to $315.3 million in 2024, then soared by 107.49% to $654.3 million in 2025.
  • The last three reported values for Invested Capital were $654.3 million (Q4 2025), $258.2 million (Q3 2025), and $305.9 million (Q2 2025) per Business Quant data.